Skip to main content

Korro Bio, Inc.

corporate_fare Company Profile

Korro Bio, Inc.

KRRO·NASDAQ·Life Sciences·CIK 0001703647

We are a biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines that edit RNA. Our goal is to treat both rare and common diseases. We are building a portfolio of programs designed to use the body's natural RNA editing process to make a precise, temporary change to a single nucleoside (converting adenosine to inosine). By editing RNA instead of DNA, we aim to expand the scope of genetic medicines, offering greater precision and adjustability, which could lead to increased specificity and better long-term tolerability. Our approach uses oligonucleotides, and we plan to deliver our medicines to patients using our proprietary platform. This platform incorporates established delivery methods, such as N-acetylgalactosamine (GalNAc)-conjugated delivery for subcutaneous administration, along with our manufacturing expertise and the existing regulatory pathways for approved oligonucleotide medicines. However, the scientific evidence supporting the feasibility of developing lead candidates using our RNA editing technology is preliminary and limited. Regulatory bodies have not yet set definitive guidelines for the overall development of RNA editing therapies, and limited clinical data has been generated to date. The flexibility of RNA editing, combined with our OPERA platform, significantly expands the range of potential therapeutic targets. Large-scale genome sequencing has increasingly identified genetic variations that cause various human diseases, both rare and common. Genetic mutations, including single nucleotide variants (SNVs), linked to disease are diverse and can impact gene function and related biochemical pathways. Data show that SNVs can lead to either a loss-of-function or a gain-of-function of a gene. Additionally, most SNVs involved in complex diseases modulate gene function. By editing RNA to mimic an SNV, we aim to address unmet patient needs by temporarily modifying gene expression and the resulting protein function.

Korro Bio, Inc. (NASDAQ:KRRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for KRRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KRRO spans 8-K, 4, 10-Q, 144.

Recent high-impact activity:

  • Novo Nordisk Ends $530M RNA-Editing Pact; Korro Bio Falls 11%
  • Novo Nordisk Terminates Korro Bio Collaboration, Effective February 2027
  • 10% Owner Lynx1 Buys $885K of Korro Bio Stock in Four Open-Market Trades
  • Korro Bio Reports Preclinical KRRO-111 Data Showing Up to 95% Liver Z-AAT Reduction in AATD
  • Korro's KRRO-111 Edits SERPINA1 Up to 96% in Preclinical AATD Data, Filing Set for 1H 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.39M
Net Income
-$117.26M
Diluted EPS
-$12.48
Op. Cash Flow
-$78.56M
Free Cash Flow
-$79.08M
Operating Income
-$121.86M
Cash & Equivalents
$21.82M
Debt / Equity
0.00×
Net Margin
-18.34×
Shares Outstanding
9.42M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104156

Short Interest & Short Volume

8.18 days to cover

FINRA reported short interest of 1,749,169 shares in KRRO as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 71.1% of KRRO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,749,169 shares as of October 30, 2026
Change vs prior period▲ 0.9%
Days to cover8.18 at avg daily volume of 213,901
Daily short volume (FINRA facilities)71.1% of 33,907 shares on November 20, 2026
5-day average short volume70.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$12.19
52-week range · as of 2026-11-05 $5.2 – $38.42
Market cap
$167.18M
Volume
123.5K (0.6× avg)
3-mo avg 213.2K
Live data · 2026-11-22 05:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KRRO - Latest Insights

KRRO
Nov 05, 2026, 3:02 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.86
Real-time Price: $12.19 info
Change: -$2.67 (-18%) info
Market Cap: $167.178M info
KRRO
Nov 05, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.29
Real-time Price: $12.19 info
Change: -$4.10 (-25%) info
Market Cap: $167.178M info
KRRO
Oct 26, 2026, 6:37 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $12.02
Real-time Price: $12.19 info
Change: +$0.170 (+1%) info
Market Cap: $167.178M info
KRRO
Oct 22, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.19 info
Change: +$2.84 (+30%) info
Market Cap: $167.178M info
KRRO
Oct 22, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.19 info
Change: +$2.84 (+30%) info
Market Cap: $167.178M info
KRRO
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.97
Real-time Price: $12.19 info
Change: +$2.22 (+22%) info
Market Cap: $167.178M info
KRRO
Aug 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.95
Real-time Price: $12.19 info
Change: -$1.76 (-13%) info
Market Cap: $167.178M info
KRRO
Aug 06, 2026, 7:08 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.50
Real-time Price: $12.19 info
Change: +$0.690 (+6%) info
Market Cap: $167.178M info
KRRO
Aug 06, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.50
Real-time Price: $12.19 info
Change: +$0.690 (+6%) info
Market Cap: $167.178M info
KRRO
Jul 02, 2026, 4:41 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $14.00
Real-time Price: $12.19 info
Change: -$1.81 (-13%) info
Market Cap: $167.178M info
KRRO
Jun 23, 2026, 6:12 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $13.71
Real-time Price: $12.19 info
Change: -$1.52 (-11%) info
Market Cap: $167.178M info
KRRO
May 19, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $12.19 info
Change: +$2.39 (+24%) info
Market Cap: $167.178M info
KRRO
May 19, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $12.19 info
Change: +$2.39 (+24%) info
Market Cap: $167.178M info
KRRO
May 07, 2026, 7:08 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.34
Real-time Price: $12.19 info
Change: -$1.15 (-9%) info
Market Cap: $167.178M info
KRRO
May 07, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.34
Real-time Price: $12.19 info
Change: -$1.15 (-9%) info
Market Cap: $167.178M info
KRRO
Apr 16, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $13.68
Real-time Price: $12.19 info
Change: -$1.49 (-11%) info
Market Cap: $167.178M info
KRRO
Mar 20, 2026, 5:03 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.54
Real-time Price: $12.19 info
Change: +$1.65 (+16%) info
Market Cap: $167.178M info
KRRO
Mar 13, 2026, 5:05 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $13.25
Real-time Price: $12.19 info
Change: -$1.06 (-8%) info
Market Cap: $167.178M info
KRRO
Mar 12, 2026, 7:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $10.82
Real-time Price: $12.19 info
Change: +$1.37 (+13%) info
Market Cap: $167.178M info
KRRO
Mar 12, 2026, 4:12 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $10.61
Real-time Price: $12.19 info
Change: +$1.58 (+15%) info
Market Cap: $167.178M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets